Participated · Series A · Aug 2026

Sinumy develops fully hands-free authentication technology that leverages smartphones' Bluetooth to identify people and automatically perform authentication for gates, payments, and access control. The company reports it has improved positioning accuracy from roughly 1.5 meters to about 10 centimeters, aiming to provide fast and spoof-resistant authentication even in crowded environments. In March it conducted a hands-free authentication gate demonstration at Shirokanedai Station in collaboration with Tokyo Metro and Toshiba. Following the recent financing, Sinumy plans productization and mass production preparation for smart gates and smart spots and intends to expand joint development and PoCs in gate, access control, and payment areas. The company also plans to hire development and business development personnel and strengthen its organization, and has appointed Tomoya Yonaga as Director and COO and Shunji Yamanaka as a UI/UX advisor.

Participated · Series A · Jul 2026

CORE Biomedicine applies a lineage-based therapeutic approach to identify and target core biological pathways that define cancer cell identity, aiming to discover first- and best-in-class oncology medicines. The company intends to expand potential patient populations beyond genomics-defined groups by focusing on lineage drivers. CORE was founded by former leaders of H3 Biomedicine and operates in Boston, Tokyo and Suzhou. Following its $21 million Series A and an AMED grant to its Japanese subsidiary, CORE says it will use the funds to advance lead programs through discovery and early clinical development and to strengthen collaborations with Japanese academic and clinical partners. The company positions itself as building an innovative precision medicine business leveraging the global biotech ecosystem.

Participated · Convertible Note · Jul 2026

Rege Nephro is developing therapies for kidney disease and is advancing a clinical pipeline in the renal space. The company is preparing for clinical trials and is using interim financing to accelerate R&D and pipeline advancement. Its recent bridge financing is intended to extend cash runway and de-risk near-term development milestones ahead of a larger Series C. Rege Nephro says this capital raise is part of a longer-term strategy to strengthen its position in renal therapies. The company plans to pursue a Series C in autumn 2026 and beyond as it progresses clinical and development activities.

Participated · Series B · Jul 2026

Neusignal Therapeutics is developing NTX-083, a novel low-molecule compound intended to treat Alzheimer’s disease via a mechanism distinct from existing therapies. The company completed a physician-initiated single-dose Phase 1 trial at the University of Tokyo Hospital (Feb–Sep 2025) and a company-sponsored multiple-dose Phase 1 trial (Nov 2025–Mar 2026) in healthy adults, with both Japanese trials reporting high safety, strong tolerability, and favorable pharmacokinetics and no significant side effects. Neusignal plans to begin a Phase 1b trial in Alzheimer’s patients in the United States later this year. The company intends to use the Series B proceeds to fund that U.S. trial and to expand its workforce ahead of potential strategic alliances with global pharmaceutical firms. Neusignal originated from Tohoku University and is headquartered in Tokyo.

Participated · Series A · Jun 2026

Founded in 2022 and based in Tokyo, M2X develops a cloud-based all-in-one system for maintenance operations and AI-powered preventive maintenance. The company serves clients across 40 industries and counts major manufacturers such as Toyota Motor Kyushu, Lotte and Rengo among its customers. Since its previous funding round, M2X has reported 700% revenue growth. M2X articulates a "Zero Downtime Vision" aimed at preventing machinery failures. The recent funding is earmarked to strengthen hiring in both business and product teams as the company scales. These moves are positioned to expand M2X's deployment of its maintenance platform across industrial customers.